Full-Time

Medical Affairs Lead

Respiratory & Immunology, R&I

Posted on 4/16/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior, Expert

London, UK

In-person working requires a minimum of three days per week from the office.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a AstraZeneca referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • First Degree or equivalent experience in Medicine, Pharmacy or Life Sciences.
  • Extensive experience of working with Respiratory and Immunology medicines.
  • Track record of leadership in pharma or clinical medicine.
  • Evidence of effective team working and accountability
  • Detailed knowledge of the UK healthcare system
  • Track record of strategy creation and execution
  • Very strong communicator
Responsibilities
  • Accountable for the Medical Strategy and its performance
  • Lead strategic development and performance management of R&I clinical services.
  • Provide oversight, coaching, and mentorship to Respiratory and Immunology MAMs.
  • Provide medical input into all UK strategic and operational planning initiatives for the Business Unit.
  • Map current clinical practice, patient pathway, and clinical/expert networks for the management of R&I.
  • Develop, lead, and implement medical strategies to support the launch of AstraZeneca’s growing portfolio
  • Build a strong network with key external partners (including KEEs, payers, patient advocacy groups, etc.) to deliver clinical and patient insight, customer focus, and clinical governance into commercial objectives.
  • Represent the UK in Regional and Global Medical Affairs settings for defined therapy areas.
  • Develop and deliver pre-launch and peri-launch medical plans and activities to support healthcare system and pathway change, generate real-world evidence, and deliver omnichannel education initiatives.
  • Provide strategic leadership to the Field Medical Affairs team (MSLs) to enable delivery of field-medical objectives and Key Performance Indicators.
  • Ensure good practice requirements are fully aligned with in line with the local Quality Management System (QMS) SOP and all other AZ policies and Standards.
Desired Qualifications
  • Registered Physician (preferably GMC) or Pharmacist (General Pharmaceutical Council)
  • Member/Fellow of a Royal College or the Royal Pharmaceutical Society
  • Clinical practice experience in a UK health setting
  • Extensive experience in the pharmaceutical industry
  • Proven expertise in the ABPI Code of Practice
  • Extensive patient and customer insight through experience of working with the NHS
  • ABPI Code Nominated Signatory status.

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships, such as their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through collaboration.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • Enhertu shows promise in early-stage breast cancer treatment with improved pCR rates.
  • Calquence combination approved in EU for chronic lymphocytic leukaemia treatment.
  • AI-powered tools enhance lung cancer detection, especially in resource-constrained settings.

What critics are saying

  • Increased competition in oncology may impact AstraZeneca's market share.
  • Discontinuation of CAPItello-280 trial could lead to financial losses.
  • AI tools for lung cancer detection face data privacy and regulatory challenges.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapeutic areas.
  • The company invests heavily in R&D for innovative drug development.
  • AstraZeneca's A.Catalyst Network fosters global health innovation collaborations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
May 7th, 2025
Enhertu Improved Pcr In Early-Stage Breast Cancer

Enhertu improved pCR in early-stage breast cancer

PharmiWeb
May 7th, 2025
Enhertu Followed By Thp Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In Patients With High-Risk Her2-Positive Early-Stage Breast Cancer In Destiny-Breast11 Phase Iii Trial

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer. Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favouring Enhertu followed by THP compared to standard of care. The trial will continue to follow EFS

Bethesda Magazine
May 6th, 2025
AstraZeneca opens cell therapy manufacturing site in Rockville

AstraZeneca announced in February 2024 that it was investing in the Rockville manufacturing facility.

Cision
May 6th, 2025
Calquence Combination Approved In Eu For 1L Mcl

Calquence combination approved in EU for 1L MCL

The Indian Practitioner
May 2nd, 2025
AstraZeneca Showcases AI-Powered Tool for Lung Cancer Detection

At the European Lung Cancer Congress (ELCC) 2025, global biopharmaceutical company AstraZeneca presented a groundbreaking study that demonstrates the power of artificial intelligence (AI) in improving lung cancer risk detection, particularly in resource-constrained healthcare settings.

INACTIVE